Migraine

Migraine is a significant risk factor for postoperative nausea and vomiting, according to results of a retrospective study published in the Journal of Clinical Medicine.

Medication overuse headache is a huge problem in societies that don't have access to proper headache care as patients take more over-the-counter, readily available treatments, said Rigmor Jensen, MD, professor of neurology at The University of Copenhagen and director of the Danish Headache Center.

In an attempt to develop a multivariable predictive model for days with new-onset migraine headaches, researchers found episodic migraine attacks were not predictable based on self-prediction or on self-reported exposure to common trigger factors.

Treatment guidelines for comorbid depression and migraine are warranted to ensure optimal efficacy and avoid possible pitfalls in psychopharmacotherapy, according to study results.

According to a study published in Headache, greater occipital nerve blocks (GONB) with bupivacaine were not as effective as intravenous (IV) metoclopramide as a first-line treatment for migraineurs who presented to emergency departments.

New research published in JAMA Neurology highlights disparities in migraine based on sexual orientation in the United States.

Many women suffering from migraine say the condition affects family planning, while this finding is more prevalent among women who are younger and experience menstrual and chronic migraine.

Prevalence of restless legs syndrome is elevated among individuals with migraine according to a systematic review and meta-analysis published in Pain Research and Management.

In individuals suffering from chronic and episodic migraine, a preliminary study shows exposure to green light therapy significantly reduced headache days and improved both intensity and duration of headache attacks.

A systematic review concluded that a correlation between magnesium deficiency and headaches exists, while magnesium deficiency may be an independent risk factor for migraine.

Compared with patients with epilepsy, migraineurs tend to suffer more from psychological difficulties, according to a study published in Journal of Multidisciplinary Healthcare.

A study using real-world data from an Italian region found two-thirds of patients with chronic migraine treated with erenumab transitioned to episodic migraine within 6 months.

Using data-driven machine learning approaches, researchers analyzed patient-reported symptoms of migraine and demonstrated automated classification of headache disorders.

Using data from the Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention, researchers were able to analyze the efficacy of erenumab at ≥50%, ≥75%, and 100% thresholds for reduction in monthly migraine days.

In young college-age women, migraine was associated with several sleep issues, although no differences in sleep quality were reported between migraineurs and controls, according to a recent study.

The pathophysiology of migraine with aura in women does not involve alteration of thalamic volume, according to a study published in NeuroImage: Clinical.

In individuals under the age of 50, both total body obesity and abdominal obesity were associated with greater migraine prevalence and attack frequency, according to a study published in The Journal of Headache and Pain.

A higher number of headache-free days (HFDs) is associated with decreased headache-related disability among individuals with migraine, according to a study published in the Journal of Managed Care & Specialty Pharmacy.

Data from women with menstrual migraine enrolled in the Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention show erenumab is a safe and effective option for treating the condition

A study based on real-world data collected from the West German Headache Center at the University Hospital Essen, Germany, concluded erenumab appears to be a promising treatment option for patients with highly therapy-refractory migraine.

Chronic migraine (CM) may be associated with widespread disruption of normal white matter (WM) integrity in the brain, according to a study published in The Journal of Headache and Pain.

When it comes to ease of use, ability to self-inject, and confidence in using an erenumab-prefilled disposable autoinjector, individuals with migraine consistently endorsed the preventive treatment, according to study results published in Patient Preference and Adherence.

In patients with episodic migraine, erenumab provided sustained efficacy for the condition over the course of 1 year, according to new results from a study to evaluate the efficacy and safety of erenumab in migraine prevention (STRIVE), published in Neurology.

Current existing research highlights the important association between the increased risk of suicidal behaviors among chronic migraineurs with and without aura, in both the clinical and general population worldwide, according to a systematic review published in Frontiers in Neurology.

Positive genetic correlations of migraine with diastolic blood pressure (BP) and systolic BP exist, supporting the notions that diastolic BP plays a critical role in migraine susceptibility and BP and migraine share underlying biological mechanisms, according to a study published in Nature Communications.

The direct effect of childhood trauma on migraine is outweighed by the mediation effect of adulthood attachment, according to a study published in the International Journal of Environmental Research and Public Health.

A combination of machine learning and random optimization may aid in predicting medication overuse in migraineurs, if clinical/biochemical features, drug exposure, and lifestyle are taken into consideration, according to a study published in Computational and Structural Biotechnology Journal.

A survey conducted among migraineurs in Genova, Italy, found that during the coronavirus disease 2019 (COVID-19) quarantine, patients experienced fewer migraine attacks and less pain but exhibited moderate levels of depression correlated to migraine burden.

A recent article in the Journal of Head and Face Pain outlines strategies for migraine treatment without face-to-face visits, and describes ways health insurance companies can remove barriers to migraine care during the coronavirus disease 2019 (COVID-19) pandemic.

The American Academy of Neurology (AAN) and the American Headache Society (AHS) released updated guidance on short-term treatment of migraine in children and adolescents.